1. A baseline tool for predicting response to peginterferon alfa‐2a in HBeAg‐positive patients with chronic hepatitis B. Issue 5 (29th June 2018) Authors: Chan, H. L. Y.; Messinger, D.; Papatheodoridis, G. V.; Cornberg, M.; Xie, Q.; Piratvisuth, T.; Ren, H.; Kennedy, P. T.; Thompson, A.; Caputo, A.; Bakalos, G.; Pavlovic, V.; Lampertico, P. Journal: Alimentary pharmacology & therapeutics Issue: Volume 48:Issue 5(2018) Page Start: 547 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A genetic risk score predicts de novo hepatocellular carcinoma in hepatits c cirrhotic patients treated with direct-acting antivirals. (February 2020) Authors: Degasperi, E.; Galmozzi, E.; Pelusi, S.; D'Ambrosio, R.; Soffredini, R.; Borghi, M.; Perbellini, R.; Facchetti, F.; Iavarone, M.; Sangiovanni, A.; Valenti, L.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. Issue 5 (2nd July 2018) Authors: El Sharkawy, R.; Thabet, K.; Lampertico, P.; Petta, S.; Mangia, A.; Berg, T.; Metwally, M.; Bayoumi, A.; Boonstra, A.; Brouwer, W. P.; Smedile, A.; Abate, M. L.; Loglio, A.; Douglas, M. W.; Khan, A.; Santoro, R.; Fischer, J.; Leeming, D. J.; Liddle, C.; George, J. Journal: Alimentary pharmacology & therapeutics Issue: Volume 48:Issue 5(2018) Page Start: 564 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Add-on Peginterferon Alfa-2a significantly reduces HBsAg levels in chronic hepatitis B, HBeAg-negative, genotype D patients fully suppressed on nucleot(s)ide analogues treatment: HERMES Study Interim Analysis. (15th February 2015) Authors: Lampertico, P.; Brunetto, M.R.; Craxì, A.; Gaeta, G.B.; Rizzetto, M.; Palmieri, G.; Colombo, M. Journal: Digestive and liver disease Issue: Volume 47(2015)Supplement 1 Page Start: e28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma. (February 2019) Authors: Iavarone, M.; Galmozzi, E.; De Silvestri, A.; Casadei-Gardini, A.; Piscaglia, F.; Marisi, G.; Facchetti, F.; Faloppi, L.; Ielasi, L.; Tovoli, F.; Cimino, A.; Scartozzi, M.; Cascinu, S.; Sangiovanni, A.; Tinelli, C.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 51(2019)Supplement 1 Page Start: e38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials. (February 2019) Authors: Lampertico, P.; Younossi, Z.M.; Lawitz, E.J.; Alkhouri, N.; Wong, V. Wai-Sun; Romero-Gomez, M.; Okanoue, T.; Trauner, M.; Kersey, K.; Li, G.; Subramanian, G.M.; Myers, R.P.; Djedjos, C.S.; Han, L.; Chen, G.; Nguyen, T.; Kohli, A.; Bzowej, N.; Younes, Z.; Sarin, S. Journal: Digestive and liver disease Issue: Volume 51(2019)Supplement 1 Page Start: e25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Baseline clinical features but not TLL1 variants predicts HCC onset in Caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 8 years. Issue 1 (February 2018) Authors: Loglio, A.; Galmozzi, E.; Iavarone, M.; Grossi, G.; Viganò, M.; Facchetti, F.; Perbellini, R.; Rumi, M.G.; Sangiovanni, A.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 50:Issue 1(2018)Supplement Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Bulevirtide improves health-related quality of life measured by EQ-5D VAS in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks. (March 2023) Authors: Buti, M.; Wedemeyer, H.; Aleman, S.; Chulanov, V.; Morozov, V.; Sagalova, O.; Stepanova, T.; Gish, R. G; Lloyd, A.; Kaushik, A. M; Suri, V.; Manuilov, D.; Osinusi, A. O; Flaherty, J.; Pandey, S.; Singh, B.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 1 Page Start: S72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis D (CHD): An integrated safety analysis of 48-week data. (March 2023) Authors: Asselah, T.; Lampertico, P.; Aleman, S.; Bourliere, M.; Streinu-Cercel, A.; Bogomolov, P.; Morozov, V.; Stepanova, T.; Lazar, S.; Suri, V.; Manuilov, D.; Mercier, R.C.; Tseng, S.; Ye, L.; Flaherty, J.F.; Osinusi, A.; Brunetto, M.; Wedemeyer, H. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 1 Page Start: S74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Changes in bone mineral density during monotherapy with tenofovir disoproxil fumarate: a 6-year real life longitudinal cohort study in chronic hepatitis B caucasian patients. (February 2020) Authors: Viganò, M.; Loglio, A.; Cerini, F.; Farina, E.; Facchetti, F.; Perbellini, R.; Rumi, M.G.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗